Patients aged 16 years or older with American Joint Committee on Cancer stage ( AJCC ) stage IIB , IIC , and III cutaneous melanoma were randomly allocated ( 1:1 ) , via a central , computer-based minimisation procedure , to receive intravenous bevacizumab 7.5 mg/kg , every 3 weeks for 1 year , or to observation .